



# Pfizer Pipeline

---

As of February 28, 2014

---



# Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of February 28, 2014.
- Visit [Pfizer.com/pipeline](http://Pfizer.com/pipeline), Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

# Table of Contents

<b>Pfizer Pipeline Snapshot</b>	<b>4</b>
<b>Cardiovascular &amp; Metabolic Diseases</b>	<b>5</b>
<b>Inflammation &amp; Immunology</b>	<b>6</b>
<b>Neuroscience &amp; Pain</b>	<b>7</b>
<b>Oncology</b>	<b>8</b>
<b>Vaccines</b>	<b>9</b>
<b>Other Areas of Focus</b> <b>(including Biosimilars and Rare Diseases)</b>	<b>10</b>
<b>Projects Discontinued Since Last Update</b>	<b>11</b>

# Pfizer Pipeline Snapshot



# Pfizer Pipeline – February 28, 2014

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Prevention (US)	Registration
	▶ Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Treatment (US/EU)	Registration
	ertugliflozin (PF-04971729)	SGLT-2 Inhibitor	Diabetes Mellitus-Type 2	Phase 3
	bococizumab (RN316 ) (PF-04950615)	PCSK9 Inhibitor	Treatment of Hyperlipidemia (Biologic)	Phase 3
	▶ PF-05175157	Acetyl-CoA carboxylase Inhibitor	Diabetes Mellitus-Type 2	Phase 2
	PF-00489791	PDE5 Inhibitor	Diabetic Nephropathy	Phase 2
	PF-04634817	CCR2/5 Antagonist	Diabetic Nephropathy, Diabetic Macular Edema	Phase 2
	PF-04937319	Partial Glucokinase Activator	Diabetes Mellitus-Type 2	Phase 2
	PF-06282999		Acute Coronary Syndrome	Phase 1
	PF-06291874		Diabetes Mellitus-Type 2	Phase 1
▶ PF-06678552		Hyperlipidemia	Phase 1	



▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – February 28, 2014 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Inflammation and Immunology	Xeljanz (tofacitinib)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	Xeljanz (tofacitinib)	JAK Inhibitor	Ulcerative Colitis	Phase 3
	Xeljanz (tofacitinib)	JAK Inhibitor	Psoriatic Arthritis	Phase 3
	PD-0360324	M-CSF Inhibitor	Sarcoidosis, *Lupus (Biologic)	Phase 2
	PF-00547659	MAdCAM Inhibitor	Crohn's Disease, Ulcerative Colitis (Biologic)	Phase 2
	PF-04171327	Selective Glucocorticoid Receptor Modulator	Rheumatoid Arthritis	Phase 2
	PF-04236921	IL-6 Inhibitor	Crohn's Disease, Lupus (Biologic)	Phase 2
	PF-05285401	Multipotent Adult Progenitor Cell	Ulcerative Colitis (Biologic)	Phase 2
	PF-06473871 (EXC 001)	CTGF Inhibitor	Dermal Scarring	Phase 2
	PH-797804	P38 Inhibitor	Chronic Obstructive Pulmonary Disease	Phase 2
	Xeljanz (tofacitinib)	JAK Inhibitor	Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease, Atopic Dermatitis	Phase 2
	Dekavil		Rheumatoid Arthritis (Biologic)	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	PF-04965842		Lupus	Phase 1
	▶ PF-06263276		Psoriasis (Topical)	Phase 1
	PF-06342674		Diabetes Mellitus-Type 1 (Biologic)	Phase 1
	▶ PF-06480605		Crohn's Disease (Biologic)	Phase 1



\* Note: Additional indications in Phase 1

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – February 28, 2014 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Neuroscience & Pain	Celebrex	COX-2	Chronic Pain (US)	Registration
	Remoxy	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain (US)	Registration
	ALO-02 Oxycodone-naltrexone core	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	CR (once a day dosing)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (on clinical hold)	Phase 3
	PF-02545920	PDE10 Inhibitor	Huntington's Disease, Adjunctive Treatment for Schizophrenia	Phase 2
	PF-04360365 (ponezumab)	Beta Amyloid Inhibitor	Cerebral Amyloid Angiopathy (Biologic)	Phase 2
	PF-05212377 (SAM-760)	5HT6 Antagonist	Alzheimer's Disease	Phase 2
	tanezumab	Nerve Growth Factor Inhibitor	Cancer Pain (Biologic)	Phase 2
	PF-04958242		Schizophrenia	Phase 1
	PF-05089771		Chronic Pain	Phase 1
	PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-06273340		Acute and Chronic Pain	Phase 1
	▶ PF-06372865		Chronic Pain	Phase 1
PF-06412562		Cognitive Disorder	Phase 1	
▶ PF-06649751		Parkinson's Disease	Phase 1	



▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – February 28, 2014 (cont'd)

New Molecular Entity

New Indication or Enhancement

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Oncology	dacomitinib (PF-00299804)	pan-HER Inhibitor	1 <sup>st</sup> Line EGFR mutant Non-Small Cell Lung Cancer, *Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	inotuzumab ozogamicin	CD22-targeted cytotoxic agent	Acute Lymphoblastic Leukemia (Biologic)	Phase 3
	palbociclib (PD-0332991)	CDK 4,6 Kinase Inhibitor	1 <sup>st</sup> Line Advanced Breast Cancer, *Cancer	Phase 3
	▶ palbociclib (PD-0332991)	CDK 4,6 Kinase Inhibitor	High Risk Early Breast Cancer	Phase 3
	palbociclib (PD-0332991)	CDK 4,6 Kinase Inhibitor	Recurrent Advanced Breast Cancer	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	Xalkori (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive 1 <sup>st</sup> Line Non-Small Cell Lung Cancer, *Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Liver Cancer	Phase 2
	PF-03446962	ALK1 Inhibitor	2 <sup>nd</sup> Line Hepatocellular Carcinoma (Biologic)	Phase 2
	▶ PF-04449913	SMO (smoothened) antagonist	Acute Myelocytic Leukemia	Phase 2
	PF-05212384	PI3K Inhibitor	3rd Line Colorectal Cancer	Phase 2
	PD-0325901		Cancer (in combination with PF-05212384)	Phase 1
	PF-03084014		Cancer	Phase 1
	PF-05082566		Cancer (Biologic)	Phase 1
	PF-06263507		Cancer (Biologic)	Phase 1
	▶ PF-06463922		Cancer	Phase 1



\* Note: Additional indications in Phase 1

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



# Pfizer Pipeline – February 28, 2014 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
<b>Vaccines</b>	MnB rLP2086 (PF-05212366)	Prophylactic Vaccine	Adolescent and Young Adult Meningitis B	Phase 3
	4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)	Prophylactic Vaccine	Staph Aureus	Phase 2
	PF-05402536		Smoking Cessation	Phase 1
	PF-06425090		Clostridium Difficile Colitis	Phase 1
	PF-06444752		Asthma	Phase 1

# Pfizer Pipeline – February 28, 2014 (cont'd)

New Molecular Entity

New Indication or Enhancement

Biosimilar

Therapeutic Area	Compound Name	Mechanism of Action (Ph 2 through regulatory approval)	Indication	Phase
<b>Other Areas of Focus (Rare Diseases)</b>	tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (US)	Registration
	► Vyndaqel (tafamidis meglumine)	Transthyretin (TTR) Dissociation Inhibitor	Adult Symptomatic Transthyretin Cardiomyopathy	Phase 3
	Rivipansel (GMI-1070)	Pan-Selectin Antagonist	Vaso-occlusive crisis associated w/ Sickle Cell Disease	Phase 2
	PF-05230907		Intracerebral Hemorrhage (Biologic)	Phase 1
	PF-05280602		Hemophilia (Biologic)	Phase 1
	PF-06252616		Muscular Dystrophies (Biologic)	Phase 1
	PF-06687859		Spinal Muscular Atrophy	Phase 1
<b>Other Areas of Focus (Biosimilars)</b>	► PF-05280014 (a potential trastuzumab Biosimilar*)	erbB2 TK Inhibitor	Metastatic Breast Cancer (Biosimilar)	Phase 3
	PF-05280586 (a potential rituximab Biosimilar*)		Rheumatoid Arthritis (Biosimilar)	Phase 1
	PF-06410293 (a potential adalimumab Biosimilar*)		Rheumatoid Arthritis (Biosimilar)	Phase 1
	PF-06438179 (a potential infliximab Biosimilar*)		Rheumatoid Arthritis (Biosimilar)	Phase 1
	► PF-06439535 (a potential bevacizumab Biosimilar*)		Cancer (Biosimilar)	Phase 1
<b>Other Areas of Focus</b>	Conjugated estrogens/bazedoxifene	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms and Osteoporosis (EU)	Registration
	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention (US)	Registration
	bosutinib	Abl and src-family kinase Inhibitor	Autosomal Dominant Polycystic Kidney Disease	Phase 2



\* Biosimilarity has not yet been established by regulators and is not claimed.

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Projects Discontinued from Development since November 8, 2013

New Molecular Entity

New Indication or Enhancement

Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
dacomitinib (PF-00299804)	pan-HER Inhibitor	Previously Treated Advanced Non-Small Cell Lung Cancer	Phase 3
Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
anrukinzumab (IMA-638)	IL-13 Inhibitor	Ulcerative Colitis (Biologic)	Phase 2
Dacomitinib (PF-00299804)	pan-HER Inhibitor	Cancer	Phase 2
PF-03049423	PDE5 Inhibitor	Stroke Recovery	Phase 2
PF-05231023		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
PF-06305591		Chronic Pain	Phase 1
RN317 (PF-05335810)		Hyperlipidemia (Biologic)	Phase 1